Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Mr Prabhakar Rajan
bci-theratest@qmul.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - THERApy de-escalation for TESTicular cancer
Back

THERApy de-escalation for TESTicular cancer

Recruiting

Open to: Male

Age: Mixed

London Sutton

Medical Conditions

Patients with testicular seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3 cm IIB will be assessed for robot-assisted retroperitoneal lymph node dissection (rRPLND)

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


THERATEST is looking to collect data from patients with testicular cancer actively receiving de-escalation treatments or other standard-of-care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients’ cancers and quality of life, whether a larger study should proceed with these treatments, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study, improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. THERATEST aims to bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

12 Aug 2024 28 Feb 2027

Publications

2025 Protocol article in https://pubmed.ncbi.nlm.nih.gov/40746851/ (added 04/08/2025)

Eligible participants will receive one of two possible treatment strategies:

De-escalation treatment with Carboplatin AUC 10 at 21-day intervals. Each 21-day interval is called a cycle. Carboplatin is administered by injecting it into a vein through a cannula over approximately 60 minutes in a hospital. Three cycles of this treatment will be given.

OR

Other types of standard-of-care treatments such as combination chemotherapy (e.g. bleomycin, etoposide and platinum (BEP) or etoposide and platinum (EP)) or radiotherapy. These will be offered to participants if they do not wish to receive Carboplatin AUC10 or if their doctor believes this is not the best treatment option for them. The details of the duration and frequency of these treatments will be given to them by your doctor.

After completing the treatment, participants will be followed for 2 years. This will allow the collection of data on long-term side effects, how well the treatment controlled the growth of the cancer as well as the impact it had on quality of life. All visits will be in line with standard-of-care visits and they will not have to attend additional hospital visits.


Patients with testicular cancer aged from 16 to 100 years old

You can take part if:



You may not be able to take part if:


A patient will not be eligible for inclusion in this study if any of the following criteria apply:1. Raised AFP > 10ng/ml that does not fall to <10ng/ml following orchidectomy2. Previous chemotherapy or radiotherapy for the disease under study.3. Previous or concurrent malignancy other than testicular cancer, unless treated with curative intent and with no known active disease present for ≥2 years before enrolment and felt to be at low risk for recurrence by the treating physician (for example: non-melanoma skin cancer or lentigo maligna; breast ductal carcinoma in situ; prostatic intraepithelialneoplasia; urothelial papillary non-invasive carcinoma or urothelial carcinoma in situ).4. Any condition that, in the opinion of the investigator, would interfere with the evaluation of study intervention or interpretation of patient safety or study results such as medical comorbidities impacting on QoL or medical conditions or other disorders that would affect adherence to study requirements.


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Barts Health NHS Trust
    The Royal London Hospital 80 Newark Street
    London
    E1 2ES
  • Royal Marsden Hospital
    Royal Marsden Hospital Downs Road
    Sutton
    SM2 5PT

This trial aims to find out information that may help people with testicular cancer. The treatments participants will receive are the same as standard-of-care treatments. There is no additional benefit over and above the standard of care.

Mr Prabhakar Rajan
bci-theratest@qmul.ac.uk



The study is sponsored by Queen Mary University of London and funded by Barts Charity.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN61007118

Or CPMS 59883

Last updated 18 February 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top